2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow Subcutaneous Emphysema: new trials by email Literature Review of Subcutaneous Emphysema trials Research Report on Subcutaneous Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin, Placebo - Alpha 1-Antitrypsin Deficiency | Phase 3 | Terminated | Kamada, Ltd. | 98 | 2019-11-25 | 2026-08-12 |
| Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg - Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 3 | Terminated | Baxalta now part of Shire | 7 | 2016-11-02 | 2021-05-13 |
alpha 1-Antitrypsin Deficiency (2) · Pulmonary Disease, Chronic Obstructive (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Emphysema (2) · Genetic Diseases, Inborn (2) · Liver Diseases (2) · Lung Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Chronic Disease (1) · Disease Attributes (1) · Lung Diseases, Obstructive (1)
alpha 1-Antitrypsin (2) · Inhalation (1)
Baxalta now part of Shire (1) · Kamada, Ltd. (1)
Australia (1) · Belgium (1) · Canada (1) · Finland (1) · Ireland (1) · Netherlands (1) · Sweden (1) · United Kingdom (1) · United States (1)
Jan Stolk, Prof (1)